Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest National Institute of Allergy and Infectious Diseases Stories

2013-09-09 08:56:31

National Institutes of Health (NIH) scientists report that a combination of two licensed antiviral drugs reduces virus replication and improves clinical outcome in a recently developed monkey model of Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Their study, which appears as a letter in the Sept. 8 edition of Nature Medicine, expands on work published in April showing that a combination of ribavirin and interferon-alpha 2b stops MERS-CoV from replicating in cell culture....

2013-09-09 08:27:20

CAMBRIDGE, Mass., Sept. 9, 2013 /PRNewswire/ -- ImmusanT announced today that Ferdinand E. Massari, MD has joined the biopharmaceutical company as Senior Vice President, Development and Chief Medical Officer. Dr. Massari will oversee the clinical development program for the therapeutic vaccine Nexvax2® for celiac disease and its companion diagnostic, as well as future development programs for other autoimmune diseases. (Logo: http://photos.prnewswire.com/prnh/20130909/LA75726LOGO)...

2013-09-05 08:28:20

Presentation to be Webcast Live, 11:40 AM EDT, September 9th PRINCETON, N.J., Sept. 5, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 15(th)...

2013-08-23 10:38:07

NIH-funded study provides more evidence supporting development of noninvasive tests Levels of a protein in the urine of kidney transplant recipients can distinguish those at low risk of developing kidney injury from those at high risk, a study suggests. The results also suggest that low levels of this protein, called CXCL9, can rule out rejection as a cause of kidney injury. The study appears online Aug. 22 in the American Journal of Transplantation. The work was funded by the National...

Drugmaker Develops 100 Percent Effective Malaria Vaccine
2013-08-08 15:25:03

Lawrence LeBlond for redOrbit.com - Your Universe Online A team of scientists have for the first time developed a vaccine for malaria that has been found to be 100 percent effective in a small clinical trial. The vaccine, known as PfSPZ Vaccine, was developed by Sanaria Inc. in Rockville, Maryland and has so far been shown to be safe, generating an immune system response in healthy adults. Publishing the results of the early-stage clinical trial in the August 8 issue of Science,...

2013-07-08 08:26:34

Access to SciClone Oral Mucositis Clinical Data Enables Personalized Medicine Approach for Design of Clinical Trials PRINCETON, N.J., July 8, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced a personalized medicine collaboration with SciClone...

2013-06-28 08:23:36

PRINCETON, N.J., June 28, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that it has enrolled and treated all patients in the Phase 1 Study BDP-PCD-01; the first clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for...

2013-06-26 08:30:40

PRINCETON, N.J., June 26, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) ("Soligenix" or the "Company"), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that on June 25, 2013 it closed its previously announced registered public offering. The Company raised gross proceeds of approximately $7.1 million in the offering and intends to...

2013-06-21 08:24:43

PRINCETON, N.J., June 21, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) ("Soligenix" or the "Company"), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today the pricing of a registered public offering of shares of common stock and warrants to purchase common stock. In connection with the public offering, the Company has entered into...

2013-05-21 23:27:00

Inflamax Research today announces a collaboration with the Immune Tolerance Network (ITN), which is funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH), to conduct clinical research into the underlying mechanisms of allergy. Mississauga, Ontario (PRWEB) May 21, 2013 Inflamax scientists worked closely with internationally renowned expert scientists of the ITN to design the study, which will provide critical insight...